Oligonucleotide Market to Surge
A new market report projects the global oligonucleotide therapeutics market will reach $17.70 billion by 2030. The growth is driven by strategic investments in ASO and siRNA platforms and advances in drug delivery technologies. This positions the field as a cornerstone of next-generation drug development.
- The global market for oligonucleotide therapeutics was valued at approximately $5.92 billion in 2024 and is projected to grow to $7.19 billion in 2025. This growth is partly driven by increasing government support for genomics and precision medicine. Neurological disorders currently represent the largest segment of the market. - Antisense oligonucleotides (ASOs) are single-stranded DNA or RNA molecules that bind to target mRNA to prevent a protein from being made. In contrast, small interfering RNAs (siRNAs) are double-stranded RNA molecules that guide a protein complex to cleave the target mRNA, effectively silencing the gene. - The first FDA-approved oligonucleotide drug was fomivirsen (Vitravene) in 1998, an ASO for treating cytomegalovirus retinitis in patients with AIDS. Since 2016, the FDA has been approving roughly two new oligonucleotide drugs each year. - A major challenge in this field is delivering the oligonucleotide drugs to the correct tissues in the body. Current successful delivery methods include GalNAc conjugation, which targets the liver, and encapsulation in lipid nanoparticles (LNPs). Researchers are actively developing new methods, like antibody-oligonucleotide conjugates, to target other tissues. - Leading companies in this space include Biogen, known for the ASO drug Spinraza for spinal muscular atrophy, and Alnylam Pharmaceuticals, which focuses on siRNA therapies. Sarepta Therapeutics is also a key player with its exon-skipping ASO drugs for Duchenne muscular dystrophy. - Developing these therapies requires a diverse team of specialists. Technical roles include oligonucleotide chemists who design and synthesize the drug molecules, and computational biologists or bioinformaticians who analyze genomic data to identify drug targets. Patient-facing roles involve clinical research professionals who manage clinical trials and genetic counselors who work with patients with the genetic disorders these drugs often target. - Careers in the technical side, like bioinformatics, often require a strong background in biology, computer science, and statistics, with many roles requiring a master's degree or Ph.D. Patient-facing careers in clinical research can stem from backgrounds in life sciences or nursing, and also frequently require advanced degrees.
